Intravenous Remifentanil Analgaesia for an Obstetric Patient with Type I Neurofbromatosis and a Factor V Leiden Mutation
Journal Title: Sultan Qaboos University Medical Journal - Year 2017, Vol 17, Issue 4
Abstract
Type I neurofbromatosis is characterised by altered skin pigmentation and the growth of benign tumours, particularly along the peripheral nerves and central nervous system. We report a 36-year-old primigravida woman in labour who was admitted to the obstetric suite of the Hospital Sant Joan de Déu, Barcelona, Spain, in 2007 with hypothyroidism, type I neurofbromatosis and a factor V Leiden mutation. Due to a lack of cranial and spinal imaging data, an epidural was not indicated; instead, continuous intravenous remifentanil analgaesia was administered. Te remifentanil infusion was self-titrated by the patient using a visual analogue scale, with the dosage ranging from 0.01 to 0.25 μg/kg/minute. Due to rotational dystocia, Kjelland-type forceps were used during the delivery. After birth, the infant was found to have Apgar scores of 9 and 10, with no maternal or neonatal adverse effects observed. Although still controversial, remifentanil may be a successful alternative for analgaesia in similar cases; however, the specifc risks and benefts for each patient should be considered prior to administration.
Authors and Affiliations
José L. Gálvez| Department of Anaesthesiology, Resuscitation & Pain Therapeutics, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, Carlos L. Errando| Departments of Surgical Services and Anaesthesiology, Resuscitation & Pain Therapeutics, Consorcio Hospital General Universitario de Valencia, Valencia, Spain, Silvia Serrano| Department of Anaesthesiology, Resuscitation & Pain Therapeutics, Hospital Sant Joan de Déu, Barcelona, Spain, Marga Martín-Ayuso| Department of Anaesthesiology, Resuscitation & Pain Therapeutics, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, José M. Valverde-Mantecón| Department of Anaesthesiology, Resuscitation & Pain Therapeutics, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
Keywords
Related Articles
- EP ID EP14827
- DOI 10.18295/squmj.2017.17.04.016
- Views 341
- Downloads 17
What are our Options in the Fight against Breast Cancer?
Eccrine Syringofbroadenoma of the Eyelid
Utility of Magnetic Resonance Imaging T2* in Diagnosing and Monitoring Severe Cardiac and Hepatic Siderosis
Chronic Myeloid Leukaemia A paradigm for malignancy or just a strange disease?
Chronic myeloid leukaemia (CML), previously a fatal illness, is now readily manageable with oral medication. First described in the 1840s, there was no widely accepted cure until the advent of allogeneic stem cell tran...
Antiphosphatidyl Serine Autoantibodies and Premature Coronary Events
Objectives: To determine whether antiphosphatidyl serine autoantibodies (aPS) are associated with increased risk of occurrence of coronary events in selected patients. Methods: Tis study compared 50 patients with corona...